$METIS TECHBIO-P(07666.HK) fell five or six points, and it fell more among the unprofitable small-cap AI pharmaceutical stocks; on the other hand, $LONGBIO-B(01779.HK) rose three or four points, $REMEGEN(09995.HK) rose slightly, $CSPC PHARMA(01093.HK) fell slightly. This batch of Hong Kong stock innovative drug stocks is moving very divergently. Capital seems to be switching within the innovative drug sector—from long-term narratives like AI pharmaceuticals to targets like Rongchang and Tianchen that have clinical progress or commercialization expectations. Targets with closer catalysts are more favored, while pure narrative ones are being abandoned first. Do you think this round of correction in AI pharmaceuticals has bottomed out?